Swiss Stocks Decline From a Six-Month High, Novartis Leads Drop

[Titanic II]

Bloomberg January 20, 2012, 12:25 PM EST

Novartis AG slid 4 percent as European regulators started a review of its Gilenya pill for multiple sclerosis

Novartis retreated 4 percent to 52.05 Swiss francs, the biggest drop since August. The European Medicines Agency started a review of Gilenya after 11 deaths among patients who received treatment.

 

[Anonymous]

Bloomberg January 20, 2012, 12:25 PM EST

Novartis AG slid 4 percent as European regulators started a review of its Gilenya pill for multiple sclerosis

Novartis retreated 4 percent to 52.05 Swiss francs, the biggest drop since August. The European Medicines Agency started a review of Gilenya after 11 deaths among patients who received treatment.

As predited. I heard from some top financial guys that it may go down to 30 by summer before the next rumored layoff. I recommend selling your stock options now or you will have nothing. Althougt it probably was not much o begin with.